A5007605375- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Cancer, Lipids, and Metabolism
- Endometriosis Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Lipoproteins and Cardiovascular Health
- Economic and Financial Impacts of Cancer
- COVID-19 and healthcare impacts
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- Estrogen and related hormone effects
- Biomedical Ethics and Regulation
- Renal cell carcinoma treatment
- Uterine Myomas and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Ethics in Clinical Research
- Cardiac, Anesthesia and Surgical Outcomes
- Cervical Cancer and HPV Research
- HER2/EGFR in Cancer Research
- Reproductive Biology and Fertility
NYU Langone Health
2016-2025
Gynecologic Oncology Group
2004-2025
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2018-2024
New York University
2014-2024
Bellevue Hospital Center
2023
Duke University
2023
GTx (United States)
2023
Columbia University
2005-2021
Memorial Sloan Kettering Cancer Center
2002-2021
Chung-Ang University
2021
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients recurrent ovarian cancer after platinum-based chemotherapy, regardless the presence or absence BRCA mutations. The efficacy niraparib in newly diagnosed advanced a response to first-line chemotherapy is unknown.In this randomized, double-blind, phase 3 trial, we randomly assigned 2:1 ratio receive placebo once daily...
Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in treatment endometrial cancer.We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial. Eligible patients with primary advanced stage III or IV first recurrent cancer were randomly assigned 1:1 ratio to receive either dostarlimab (500 mg) placebo, plus carboplatin (area under...
Abstract Recurrent karyotypic abnormalities are a characteristic feature of cervical cancer (CC) cells, which may result in deregulated expression important genes that contribute to tumor initiation and progression. To examine the role gain long arm chromosome 20 (20q), one common chromosomal gains CC, we evaluated CC at various stages progression using single nucleotide polymorphism (SNP) array, gene profiling, fluorescence situ hybridization (FISH) analyses. This analysis revealed copy...
Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding PD-L1 and PD-L2. We report interim data from patients endometrial cancer (EC) participating phase I trial single-agent dostarlimab. Methods GARNET, an ongoing, single-arm, open-label, intravenous dostarlimab advanced solid tumors, being undertaken at 123 sites. Two cohorts EC were recruited: those dMMR/MSI-H disease (cohort A1) proficient/stable (MMRp/MSS) A2)....
High-grade serous ovarian cancer (HGSOC) is hallmarked by early onset of peritoneal dissemination, which distinguishes it from low-grade (LGSOC). Here, we describe the aggressive nature HGSOC ascitic tumor cells (ATCs) characterized integrin α5high (ITGA5high) ATCs, are prone to forming heterotypic spheroids with fibroblasts. We term these aggregates as metastatic units (MUs) in for their advantageous capacity and active involvement dissemination. Intriguingly, fibroblasts inside MUs support...
To report updated long-term efficacy and safety from the double-blind, placebo-controlled, phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016).Patients with newly diagnosed advanced ovarian cancer complete or partial response (CR PR) to first-line platinum-based chemotherapy received niraparib placebo once daily (2:1 ratio). Stratification factors were best regimen (CR/PR), receipt of neoadjuvant (yes/no), homologous recombination deficiency (HRD) status (deficient [HRd]/proficient [HRp]...
BackgroundPart 1 of the RUBY trial (NCT03981796) evaluated dostarlimab plus carboplatin-paclitaxel compared with placebo in patients primary advanced or recurrent endometrial cancer. At first interim analysis, met one its dual-primary endpoints statistically significant progression-free survival benefits mismatch repair deficient/microsatellite instability–high (dMMR/MSI-H) and overall populations. Overall (OS) results are reported from second analysis.Patients MethodsRUBY is a phase 3,...
To determine the accuracy of spiral computed tomography (CT) in depiction peritoneal metastases by using surgical findings patients with ovarian cancer as standard reference.Three independent readers reviewed preoperative CT scans obtained 64 who underwent primary surgery for cancer. Readers rated likelihood on a five-point scale and recorded presence or absence ascites, parietal thickening enhancement, small-bowel wall distortion. Peritoneal were identified nodular, plaquelike, infiltrative...
Abstract Cervical cancer (CC) cells exhibit complex karyotypic alterations, which is consistent with deregulation of numerous critical genes in its formation and progression. To characterize this complexity at the molecular level, we used cDNA array comparative genomic hybridization (aCGH) to analyze 29 CC cases identified a number over represented deleted genes. The aCGH analysis revealed least 17 recurrent amplicons six common regions deletions. These contain several known tumor‐associated...
Abstract Patients with advanced stage invasive cervical cancer (CC) exhibit highly complex genomic alterations and respond poorly to conventional treatment protocols. In our efforts understand the molecular genetic basis of CC, we examined role Fanconi Anemia (FA)-BRCA pathway. Here, show that FANCF gene is disrupted by either promoter hypermethylation and/or deregulated expression in a majority CC. Inhibition DNA methylation histone deacetylases induces re-expression CC cell lines....
Abstract Purpose: This interim report of the GARNET phase I trial presents efficacy and safety dostarlimab in patients with advanced or recurrent endometrial cancer (EC), an analysis tumor biomarkers as prognostic indicators. Patients Methods: A total 153 mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) 161 proficient (MMRp)/microsatellite stable (MSS) EC were enrolled dosed. received 500 mg every 3 weeks for four cycles, then 1,000 6 until progression. Primary...
PURPOSE Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor patients advanced or recurrent EC. PATIENTS AND METHODS ENGOT-EN5/GOG-3055/SIENDO a randomized, prospective, multicenter, double-blind, placebo-controlled, phase III study at 107 sites 10 countries. Patients 18 years older...
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell and differentiation, is overexpressed in several tumor types, including breast, gastric colorectal cancer. HER2-targeted therapies have shown clinical activity against these resulting regulatory approvals. However, the efficacy of HER2 tumors with mutations has not been widely investigated. SGNTUC-019 an open-label, phase basket study evaluating tucatinib, a tyrosine kinase inhibitor, combination...